Now, there could be another alternative, in the form of eye drops administered daily, according to AbbVie's Allergan subsidiary, which reported new phase 3 data for its pilocarpine formulation ...

Allergan is still on the acquisition trail following its failed merger with Pfizer, spending $85 million to acquire privately-held Topokine Therapeutics and its late-stage product for under-eye bags.

It was then that Actavis, a drug company that specializes in generic drugs and over-the-counter products, scooped up Allergan for a neat $66 billion. Here's a photo of Actavis CEO Brenton Saunders ...

Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan ...